MeSH D003234 - bacterial conjunctivitis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Ciprofloxacin | Ciprofloxacin | 2004-06-09 | |||
| Ofloxacin | Ofloxacin | 2003-09-02 | ||||
| Taro Pharmaceutical | Ciprofloxacin | Ciprofloxacin | 2004-10-06 | |||
| NATCO Pharma | Ciprofloxacin | Ciprofloxacin | 2004-06-09 | |||
| Johnson & Johnson | Ofloxacin | Floxin | 1990-12-28 | |||
| Lupin Research | Gatifloxacin | Gatifloxacin | 2013-08-28 | |||
| Loteprednol etabonate | Loteprednol Etabonate | 2023-12-26 | ||||
| Sandoz | Gatifloxacin | Gatifloxacin | 2016-07-11 | |||
| Ofloxacin | Ofloxacin | 2004-05-14 | ||||
| Ciprofloxacin | Ciloxan | 1990-12-31 | ||||
| Hydrocortisone, Ciprofloxacin | Cipro | 1998-02-10 | ||||
| Dexamethasone, Ciprofloxacin | Ciprodex | 2025-06-04 | 2003-07-18 | |||
| Bausch Health Companies | Loteprednol etabonate | Alrex | 1998-03-09 | |||
| Besifloxacin | Besivance | 2029-11-13 | 2009-05-28 | |||
| Loteprednol etabonate | Lotemax | 1998-03-09 | ||||
| Loteprednol etabonate | Lotemax Sm | 2036-01-26 | 2019-02-22 | |||
| Ofloxacin | Ofloxacin | 2008-03-17 | ||||
| Tobramycin, Loteprednol etabonate | Zylet | 2004-12-14 | ||||
| Allergan | Ofloxacin | Ocuflox | 1993-07-30 | |||
| Gatifloxacin | Zymar | 2003-03-28 | ||||
| Ciprofloxacin | Ciprofloxacin | 2005-01-21 | ||||
| Bayer | Ciprofloxacin | Cipro | 1987-10-22 |
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
100%1/1
Phase 2
89%8/9
Phase 3
56%14/25
Approved: 6Overall Success rate: 50%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use